erlotinib hydrochloride has been researched along with monensin in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (monensin) | Trials (monensin) | Recent Studies (post-2010) (monensin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,336 | 115 | 424 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI | 1 |
| Cao, D; Chen, X; Feng, Y; Gong, C; Haydon, RC; He, TC; Huang, B; Huang, S; Lei, Y; Liu, B; Liu, W; Liu, X; Luo, W; Luu, HH; Ma, C; Peng, B; Shen, Y; Tang, S; Wang, X; Wu, T; Wu, X; Yang, L; Ye, Z; Yuan, C; Zeng, Z; Zhang, B; Zhang, L; Zhang, Z; Zhao, L | 1 |
2 other study(ies) available for erlotinib hydrochloride and monensin
| Article | Year |
|---|---|
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Monensin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2014 |
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Mice; Mice, Nude; Monensin; Pancreas; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |